Google DeepMind launches AlphaGenome 2 to model DNA mutations in specific cells

Google DeepMind released AlphaGenome 2, an artificial intelligence system built to predict how small changes in human DNA alter gene activity inside individual cell types. While every human cell contains identical genetic code, different cells read that code uniquely to function as heart tissue, brain cells, or immune defenders. The new software moves beyond older tools that averaged genetic data across entire organs, allowing researchers to inspect microscopic changes within specific cell states.

Many human diseases are triggered by subtle genetic mutations that only disrupt a specific kind of cell. By predicting how millions of potential DNA changes influence distinct cells, the technology could help scientists zero in on the precise origin of complex conditions or rare genetic disorders. This finer resolution could accelerate drug discovery and help medical researchers identify potential targets for new treatments far faster than traditional methods allow.

Despite these digital predictions, computational models still require extensive laboratory testing before leading to approved therapies. It remains uncertain how quickly clinical research teams outside tech-funded labs can turn these computational insights into real-world treatments. Furthermore, while mapping cell-level mutations is a major technical advance, converting digital forecasts into safe medical interventions presents biological hurdles that algorithms alone cannot resolve.